90 related articles for article (PubMed ID: 8243329)
1. Identification of a receptor for human müllerian inhibiting substance.
Catlin EA; Ezzell RM; Donahoe PK; Gustafson ML; Son EV; MacLaughlin DT
Endocrinology; 1993 Dec; 133(6):3007-13. PubMed ID: 8243329
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
3. Identification of müllerian inhibiting substance specific binding in human cell lines.
MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK
Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
5. Mullerian inhibiting substance binding and uptake.
Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
[TBL] [Abstract][Full Text] [Related]
6. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
[TBL] [Abstract][Full Text] [Related]
7. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
8. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
9. Localization of Mullerian inhibiting substance receptors in various human cancer cell lines.
Rodina AV; Gukasova NV; Makarov VA; Kondrasheva IG; Khomyakova AV; Posypanova GA; Popova ON; Moskaleva EY; Severin SE
Biochemistry (Mosc); 2008 Jul; 73(7):797-805. PubMed ID: 18707588
[TBL] [Abstract][Full Text] [Related]
10. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
[TBL] [Abstract][Full Text] [Related]
12. Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells.
Lee MM; Seah CC; Masiakos PT; Sottas CM; Preffer FI; Donahoe PK; Maclaughlin DT; Hardy MP
Endocrinology; 1999 Jun; 140(6):2819-27. PubMed ID: 10342873
[TBL] [Abstract][Full Text] [Related]
13. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
14. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
15. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone.
di Clemente N; Wilson C; Faure E; Boussin L; Carmillo P; Tizard R; Picard JY; Vigier B; Josso N; Cate R
Mol Endocrinol; 1994 Aug; 8(8):1006-20. PubMed ID: 7997230
[TBL] [Abstract][Full Text] [Related]
16. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
17. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
[TBL] [Abstract][Full Text] [Related]
18. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
19. Müllerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids.
Kuroda T; Lee MM; Ragin RC; Hirobe S; Donahoe PK
Endocrinology; 1991 Dec; 129(6):2985-92. PubMed ID: 1954882
[TBL] [Abstract][Full Text] [Related]
20. Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects.
Ragin RC; Donahoe PK; Kenneally MK; Ahmad MF; MacLaughlin DT
Protein Expr Purif; 1992 Jun; 3(3):236-45. PubMed ID: 1392620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
